Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Lilly's speedy $8 billion Loxo Oncology acquisition was 'not competitive,' according to analyst assessments, with the deal announced at J.P. Morgan Healthcare…
Retevmo (selpercatinib) generated worldwide sales of $364 million in 2024 ($456 million in 2023); not a major sales driver given the rarity of the RET…
U.S. FDA approves expanded indication for Lilly’s Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Eli Lilly acquired Loxo Oncology for approximately $8 billion ($235 per share) in an all-cash tender offer, gaining a precision oncology pipeline anchored by Vitrakvi (larotrectinib), the first tumor-agnostic TRK inhibitor approved by the FDA, and the RET inhibitor selpercatinib (LOXO-292).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Loxo Oncology, Inc. (this deal) | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2019 deals · Eli Lilly and Company deals · Oncology deals